Positives

• A PNH patient who switched from the every-two-week predecessor reported just six or seven infusions per year, which dramatically reduced infusion-day exhaustion and missed work Drugs.com.
  
  
• Adults in atypical HUS trials experienced rapid hematologic and renal improvements with no unexpected adverse events on the eight-week schedule PubMed.
  
  

Negatives

• A user reported ongoing upper respiratory infections and headaches as the most common complaints on long-term dosing Drugs.com.
  
  
• Patients in head-to-head studies noted no measurable additional improvement in fatigue scores compared with the older C5 inhibitor at 26 weeks, despite the dosing convenience PMC.
  
  

Hurdles & Side Effects

• Patients reported that prescribers will only consider this drug for labeled hematologic indications, leaving Long COVID patients with complement activation unable to access it PMC.
  
  
• A patient described the requirement for meningococcal vaccination at least two weeks before the first dose and ongoing carrier-monitoring as an additional infection-related burden Drugs.com.